Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 109pembrolizumab 93Pemetrexed 83Cisplatin 67Specimen Handling 41durvalumab 36Paclitaxel 36Nivolumab 33Docetaxel 33atezolizumab 30Magnetic Resonance Spectroscopy 30osimertinib 29Radiotherapy 21Gemcitabine 21Etoposide 21130-nm albumin-bound paclitaxel 19Cetuximab 17amivantamab 14Radiosurgery 13Radiation 12Platinum 12Bevacizumab 12lazertinib 11cemiplimab 11Taxes 11Immunoglobulin G 11Topotecan 10Ipilimumab 10Drug Therapy 10Disulfides 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
iadademstat × Thoracic × 30 days × Clear all
NCT06287775 2026-05-22

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡